Bank of New York Mellon’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.29M | Sell |
767,567
-45,839
| -6% | -$66.6K | ﹤0.01% | 3210 |
|
|
2026
Q1 | $1.07M | Sell |
813,406
-21,167
| -3% | -$37.9K | ﹤0.01% | 3165 |
|
|
2025
Q4 | $1.56M | Buy |
834,573
+29,017
| +4% | +$55.8K | ﹤0.01% | 2985 |
|
|
2025
Q3 | $1.03M | Sell |
805,556
-82,910
| -9% | -$112K | ﹤0.01% | 3197 |
|
|
2025
Q2 | $1.1M | Buy |
888,466
+24,827
| +3% | +$28.7K | ﹤0.01% | 3081 |
|
|
2025
Q1 | $1.02M | Sell |
863,639
-4,340,328
| -83% | -$6.66M | ﹤0.01% | 3058 |
|
|
2024
Q4 | $9.52M | Sell |
5,203,967
-369,200
| -7% | -$721K | ﹤0.01% | 1949 |
|
|
2024
Q3 | $9.47M | Sell |
5,573,167
-4,362,004
| -44% | -$7.17M | ﹤0.01% | 1960 |
|
|
2024
Q2 | $13.6M | Sell |
9,935,171
-1,440,228
| -13% | -$2.91M | ﹤0.01% | 1800 |
|
|
2024
Q1 | $42.7M | Buy |
11,375,399
+6,482,961
| +133% | +$38M | 0.01% | 1127 |
|
|
2023
Q4 | $48M | Buy |
4,892,438
+489,639
| +11% | +$4M | 0.01% | 1066 |
|
|
2023
Q3 | $36.8M | Buy |
4,402,799
+2,514,656
| +133% | +$28.7M | 0.01% | 1178 |
|
|
2023
Q2 | $25.1M | Buy |
1,888,143
+393,237
| +26% | +$4.78M | 0.01% | 1425 |
|
|
2023
Q1 | $17.3M | Buy |
1,494,906
+530,864
| +55% | +$5.28M | ﹤0.01% | 1625 |
|
|
2022
Q4 | $7.89M | Buy |
964,042
+1,652
| +0.2% | +$14.2K | ﹤0.01% | 2056 |
|
|
2022
Q3 | $5.59M | Buy |
962,390
+115,158
| +14% | +$661K | ﹤0.01% | 2238 |
|
|
2022
Q2 | $3.75M | Sell |
847,232
-149,812
| -15% | -$910K | ﹤0.01% | 2477 |
|
|
2022
Q1 | $9.07M | Sell |
997,044
-9,695
| -1% | -$112K | ﹤0.01% | 2116 |
|
|
2021
Q4 | $20.6M | Buy |
1,006,739
+11,720
| +1% | +$283K | ﹤0.01% | 1709 |
|
|
2021
Q3 | $25.4M | Buy |
995,019
+41,230
| +4% | +$1.22M | 0.01% | 1584 |
|
|
2021
Q2 | $33.4M | Sell |
953,789
-9,242
| -1% | -$269K | 0.01% | 1433 |
|
|
2021
Q1 | $32.1M | Sell |
963,031
-41,989
| -4% | -$1.47M | 0.01% | 1420 |
|
|
2020
Q4 | $26.1M | Sell |
1,005,020
-17,838
| -2% | -$303K | 0.01% | 1476 |
|
|
2020
Q3 | $10.1M | Buy |
1,022,858
+1,295
| +0.1% | +$7.46K | ﹤0.01% | 1848 |
|
|
2020
Q2 | $3.52M | Sell |
1,021,563
-47,611
| -4% | -$162K | ﹤0.01% | 2381 |
|
|
2020
Q1 | $3.27M | Buy |
1,069,174
+858
| +0.1% | +$3.51K | ﹤0.01% | 2290 |
|
|
2019
Q4 | $5.49M | Sell |
1,068,316
-40,068
| -4% | -$204K | ﹤0.01% | 2295 |
|
|
2019
Q3 | $5.72M | Buy |
1,108,384
+454,281
| +69% | +$2.54M | ﹤0.01% | 2213 |
|
|
2019
Q2 | $3.96M | Buy |
654,103
+12,014
| +2% | +$84.2K | ﹤0.01% | 2449 |
|
|
2019
Q1 | $4.64M | Buy |
642,089
+21,788
| +4% | +$158K | ﹤0.01% | 2367 |
|
|
2018
Q4 | $4.59M | Buy |
620,301
+74,002
| +14% | +$469K | ﹤0.01% | 2347 |
|
|
2018
Q3 | $2.96M | Buy |
546,299
+58,409
| +12% | +$251K | ﹤0.01% | 2647 |
|
|
2018
Q2 | $1.73M | Buy |
487,890
+50,699
| +12% | +$141K | ﹤0.01% | 2941 |
|
|
2018
Q1 | $897K | Buy |
437,191
+18,785
| +4% | +$48.8K | ﹤0.01% | 3281 |
|
|
2017
Q4 | $1.1M | Sell |
418,406
-41,152
| -9% | -$144K | ﹤0.01% | 3187 |
|
|
2017
Q3 | $2.41M | Buy |
459,558
+86,415
| +23% | +$371K | ﹤0.01% | 2730 |
|
|
2017
Q2 | $1.33M | Sell |
373,143
-34,755
| -9% | -$140K | ﹤0.01% | 3086 |
|
|
2017
Q1 | $2.11M | Buy |
407,898
+17,794
| +5% | +$87.1K | ﹤0.01% | 2820 |
|
|
2016
Q4 | $1.48M | Buy |
390,104
+25,199
| +7% | +$183K | ﹤0.01% | 3040 |
|
|
2016
Q3 | $3.27M | Buy |
364,905
+6,015
| +2% | +$50.3K | ﹤0.01% | 2453 |
|
|
2016
Q2 | $2.52M | Buy |
358,890
+26,823
| +8% | +$245K | ﹤0.01% | 2582 |
|
|
2016
Q1 | $2.82M | Buy |
332,067
+10,179
| +3% | +$100K | ﹤0.01% | 2461 |
|
|
2015
Q4 | $4.23M | Sell |
321,888
-12,217
| -4% | -$110K | ﹤0.01% | 2319 |
|
|
2015
Q3 | $1.22M | Sell |
334,105
-57,279
| -15% | -$280K | ﹤0.01% | 3062 |
|
|
2015
Q2 | $2.25M | Buy |
391,384
+40,460
| +12% | +$234K | ﹤0.01% | 2831 |
|
|
2015
Q1 | $2.05M | Buy |
350,924
+19,424
| +6% | +$134K | ﹤0.01% | 2845 |
|
|
2014
Q4 | $2.6M | Buy |
331,500
+45,677
| +16% | +$292K | ﹤0.01% | 2687 |
|
|
2014
Q3 | $1.4M | Buy |
285,823
+1,611
| +0.6% | +$8.42K | ﹤0.01% | 3096 |
|
|
2014
Q2 | $1.76M | Buy |
284,212
+65,331
| +30% | +$327K | ﹤0.01% | 2978 |
|
|
2014
Q1 | $1.17M | Sell |
218,881
-15,147
| -6% | -$95.7K | ﹤0.01% | 3194 |
|
|
2013
Q4 | $1.22M | Buy |
234,028
+16,113
| +7% | +$74K | ﹤0.01% | 3184 |
|
|
2013
Q3 | $1.2M | Sell |
217,915
-889
| -0.4% | -$3.09K | ﹤0.01% | 3135 |
|
|
2013
Q2 | $554K | Buy |
+218,804
| New | +$545K | ﹤0.01% | 3461 |
|
Other funds holding PACB
IEFM
N
BLAM
CAM
Bank of New York Mellon's PACB Position: Q2 2026 in Review
Bank of New York Mellon reduced its Pacific Biosciences (PACB) stake by 5.6% in Q2 2026, selling an estimated $66.6K and leaving 767,567 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3210.
Bank of New York Mellon first reported a position in PACB in Q2 2013 and has held it in 53 quarters since. The position peaked at $48M in Q4 2023. 98 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- Bank of New York Mellon held 767,567 shares of Pacific Biosciences worth $1.29M as of Q2 2026.
- Bank of New York Mellon sold 45,839 Pacific Biosciences shares in Q2 2026, an estimated $66.6K.
- Pacific Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3210 holding.
- Bank of New York Mellon first reported a position in Pacific Biosciences in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Pacific Biosciences position peaked at $48M in Q4 2023.
- 98 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.